In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study

Jun, Kuai; Yang, Fang; Li, Guangjun; Fang, Xiang-jie; Gao, Beile

doi:10.2147/ott.s102909

Cited by 5 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During 2015–2020, substantial advancements have been achieved in T‐cell immunotherapy, particularly in hematologic malignancies. Moreover, its potential has been preliminarily explored in gastric cancer 8,9 . A study on advanced gastric cancer revealed that combining chemotherapy with T‐cell immunotherapy prolonged PFS in patients with stage III gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Individualised adjuvant immunotherapy with neoantigen‐reactive T cells for gastric signet‐ring cell carcinoma

Ding,

Liu,

et al. 2023

Clin & Trans Imm

View full text Add to dashboard Cite

ObjectivesThe signet‐ring cell carcinoma (SRCC) of the stomach is highly invasive. Patients with stage III gastric SRCC usually experience tumor recurrence within 2 years after radical surgery. Unfortunately, there is no effective treatment to postpone recurrence following adjuvant chemotherapy. Our study aimed to explore the safety and efficacy of neoantigen‐reactive T lymphocytes (NRTs) in patients with stage III gastric SRCC.MethodsThe study included 20 patients with stage III gastric SRCC who received radical surgery and adjuvant chemotherapy. Following the adjuvant chemotherapy, they underwent treatment with a range of one to four cycles of personalised neoantigen‐reactive T cells. The primary endpoint was the median progression‐free survival (mDFS). The secondary endpoint was safety and immune responses. The median duration of follow‐up was 41 months (95% CI: 39–42.9 months).ResultsOur results showed that patients who received adjuvant neoantigen‐reactive T‐cell immunotherapy demonstrated a propensity towards prolonged disease‐free survival (DFS) and overall survival (OS) in comparison to previous studies. The 2‐year DFS and OS rates reached 73.7% and 95%, respectively, whereas the 5‐year DFS and OS rates were 44% and 69%. The median DFS was 41 months (95% CI: 28.9–53.1 months) and the median OS was not reached. In addition, there was a significant increase in serum concentrations of IL‐2, IL‐4, IL‐6, IL‐10, TNF‐α and IFN‐γ after cell immunotherapy. The adverse reactions were mild.ConclusionIn conclusion, adjuvant immunotherapy with NRTs showed promising efficacy alongside a manageable safety profile.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Moreover, its potential has been preliminarily explored in gastric cancer. 8 , 9 A study on advanced gastric cancer revealed that combining chemotherapy with T‐cell immunotherapy prolonged PFS in patients with stage III gastric cancer. The 2‐year PFS of the two groups was 62.5% and 25.7%, respectively.…”

Section: Introductionmentioning

confidence: 99%

Individualised adjuvant immunotherapy with neoantigen‐reactive T cells for gastric signet‐ring cell carcinoma

Ding,

Liu,

et al. 2023

Clin & Trans Imm

View full text Add to dashboard Cite

show abstract

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

et al. 2021

View full text Add to dashboard Cite

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures

Wei

Azuma

Nakahara

et al. 2023

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitor (ICI) therapy has substantially improved the overall survival (OS) in patients with non-small-cell lung cancer (NSCLC); however, its response rate is still modest. In this study, we developed a machine learning-based platform, namely the Cytokine-based ICI Response Index (CIRI), to predict the ICI response of patients with NSCLC based on the peripheral blood cytokine profiles.MethodsWe enrolled 123 and 99 patients with NSCLC who received anti-PD-1/PD-L1 monotherapy or combined chemotherapy in the training and validation cohorts, respectively. The plasma concentrations of 93 cytokines were examined in the peripheral blood obtained from patients at baseline (pre) and 6 weeks after treatment (early during treatment: edt). Ensemble learning random survival forest classifiers were developed to select feature cytokines and predict the OS of patients undergoing ICI therapy.ResultsFourteen and 19 cytokines at baseline and on treatment, respectively, were selected to generate CIRI models (namely preCIRI14 and edtCIRI19), both of which successfully identified patients with worse OS in two completely independent cohorts. At the population level, the prediction accuracies of preCIRI14 and edtCIRI19, as indicated by the concordance indices (C-indices), were 0.700 and 0.751 in the validation cohort, respectively. At the individual level, patients with higher CIRI scores demonstrated worse OS [hazard ratio (HR): 0.274 and 0.163, and p<0.0001 and p=0.0044 in preCIRI14 and edtCIRI19, respectively]. By including other circulating and clinical features, improved prediction efficacy was observed in advanced models (preCIRI21 and edtCIRI27). The C-indices in the validation cohort were 0.764 and 0.757, respectively, whereas the HRs of preCIRI21 and edtCIRI27 were 0.141 (p<0.0001) and 0.158 (p=0.038), respectively.ConclusionsThe CIRI model is highly accurate and reproducible in determining the patients with NSCLC who would benefit from anti-PD-1/PD-L1 therapy with prolonged OS and may aid in clinical decision-making before and/or at the early stage of treatment.

show abstract

In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study

Cited by 5 publications

References 32 publications

Individualised adjuvant immunotherapy with neoantigen‐reactive T cells for gastric signet‐ring cell carcinoma

Individualised adjuvant immunotherapy with neoantigen‐reactive T cells for gastric signet‐ring cell carcinoma

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures

Contact Info

Product

Resources

About